Shares of Beam Therapeutics Inc. BEAM were down 4.7% on Jul 15 after it announced that its current chief financial officer (CFO), Terry-Ann Burrell, is stepping down from her role effective Aug 9, 2024. As part of the leadership transition process, the company is now looking for a new CFO. Terry-Ann Burrell will now take up the role of vice chairman of investment banking at JPMorgan Chase. Terry-Ann Burrell has been an integral part of BEAM’s evolution into a leading gene editing company aimed at developing precision genetic medicines through base editing. BEAM’s pipeline of gene editing therapies is based on its proprietary base editing technology. The company is advancing its base editing technology across three disease area portfolios, namely, hematology, immunology/oncology and genetic diseases. Year to date, shares of Beam Therapeutics have lost 5.8% compared with the industry’s decline of 2.7%. Zacks Investment Research Image Source: Zacks Investment Research The company is evaluating its leading ex-vivo genome-editing candidate, BEAM-101, in the phase I/II BEACON study for the treatment of adult patients with sickle cell disease, an inherited blood disorder. Dosing and engraftment for the three patients in the sentinel cohort of the BEACON study have been completed. Data from multiple patients in the study is expected in the second half of 2024. Apart from hemoglobinopathy candidates, BEAM is also expanding its genetic disease pipeline by developing BEAM-301 and BEAM-302. Last month, the company dosed the first patient in a phase I/II study to evaluate BEAM-302 for the treatment of alpha-1 antitrypsin deficiency. The study is designed to identify the optimal dosage of BEAM-302. The company will file an investigational new drug (IND) application with the FDA to begin clinical studies on BEAM-302 in the United States shortly. BEAM is also planning to initiate a clinical study on BEAM-301 for the treatment of glycogen storage disease 1a in the United States. An IND application for BEAM-301 is expected to be filed shortly. With some clinical milestones expected later in the year, it remains to be seen how the leadership transition helps Beam Therapeutics in developing a differentiated class of precision genetic medicines and driving long-term growth. Zacks Rank & Other Stocks to Consider Beam Therapeutics currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the biotech sector are ANI Pharmaceuticals, Inc. ANIP, Adaptive Biotechnologies Corporation ADPT and RAPT Therapeutics, Inc. RAPT, each carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. In the past 60 days, estimates for ANI Pharmaceuticals 2024 earnings per share have improved from $4.41 to $4.44. Earnings per share estimates for 2025 have improved from $4.85 to $5.42. Year to date, shares of ANIP have jumped 14.7%. ANIP’s earnings beat estimates in each of the trailing four quarters, the average surprise being 53.90%. In the past 60 days, estimates for Adaptive Biotechnologies’ 2024 loss per share have narrowed from $1.30 to $1.29, while loss per share estimates for 2025 have narrowed from $1.08 to $1.02. Year to date, shares of ADPT have lost 17.7%. ADPT’s earnings beat estimates in two of the trailing four quarters, meeting the same once and missing on the remaining occasion, the average surprise being 0.65%. In the past 60 days, estimates for RAPT Therapeutics’ 2024 loss per share have narrowed from $2.94 to $2.93. Loss per share estimates for 2025 have narrowed from $2.06 to $2.05. Year to date, shares of RAPT have plunged 85.7%. RAPT’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 3.19%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Beam Therapeutics Inc. (BEAM):Free Stock Analysis Report ANI Pharmaceuticals, Inc. (ANIP):Free Stock Analysis Report Adaptive Biotechnologies Corporation (ADPT):Free Stock Analysis Report Rapt Therapeutics (RAPT):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Beam Therapeutics' (BEAM) CFO to Step Down, Stock Declines
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...